Upstream Archives - BioProcess InternationalBioProcess International

Enabling Faster Feed Strategy Optimization with Rapid Spent Media Analysis and Data Visualization Tools

This webcast features: Milla Neffling, PhD, Bioprocessing Market Segment Manager, 908 Devices. Optimization of feed strategy to boost process productivity and meet critical quality attributes can greatly benefit from using real-time analytics to gain key insights into the process. Frequent measurements of key nutrients and metabolites in spent media also come with the challenge of generating daunting amounts of data. Bioprocess data visualization can therefore be a cumbersome and lengthy task when multiple dynamic key factors are considered. We highlight…

Benefits of Real-Time Analytics to Overcome Common Cell Culture Challenges

by BPI Contributor

This webcast features: Nick Randall, Bioprocessing Product Manager, 908 Devices. Faster development cycles, intensified processes, and automation of process control are key initiatives in biotherapeutics manufacturing. However, offline analytics requiring manual intervention are commonly used to monitor critical and time-sensitive process parameters. We describe a new automated approach for optimal growth and production, leveraging sensitive, on-line (sample-free) monitoring of glucose and lactate with automated feed control, and its impact on growth/viability, lower toxic metabolite, and improved PQA. Key takeaways: Explore…

Benefits of Hollow Fiber Filter Cell Expansion

by BPI Contributor

This webcast features: Stuart Gibb, PhD, Scientific Strategy Lead, Terumo Blood and Cell Technologies. Cell therapy requires cells to be healthy and active throughout the entire manufacturing process for optimal endpoint efficacy. A key part of this process is cell expansion. The Quantum Flex hollow-fiber filter technology provides an effective cell culture environment to provide ready access to fresh media, waste removal, and gas exchange over micrometer distances and works with suspension and adherent cell culture. In this environment, we…

Analytical Tools to Improve Production of Full Capsids in Initial Stages of AAV Process Development

by BPI Contributor

This webcast features: Ivana Petrović Koshmak, PhD, Head of Upstream Process Development, BIA Separations, now a Sartorius company. Empty AAV capsids are known contributors of immunogenicity in gene therapy products. Reducing them below 10% during downstream process is difficult if they constitute the vast majority of total AAV produced in harvest – the solution is a further optimization of harvest. Determining the factors that improve production of full AAVs is possible at the initial stages of upstream process development, with…

Drug Discovery: Screening Approaches for Rapid Assessment of Target Tractability

by BPI Contributor

This webcast features: Nuska Tschammer, Head of DEL Lab Operations, WuXi AppTec. In recent years, increasing use of genetic, transcriptional and knock-out technologies led to numerous biologically validated targets, many of them in the category “first-in-class”. The core purpose of experimentally based tractability assessments is to evaluate if the target of interest can be modulated by a chemical entity. In the past, extensive HTS screening efforts were initiated to find starting points for the small molecule drug discovery. Today, direct…

Improve Your Cell Line Development Workflows with Analytical Tools

by BPI Contributor

This webcast features: Dirk Müller, PhD, Manager of Media & Process Development, Sartorius, Lukas Klein, Scientist, Sartorius. Cell line development involves screening thousands of clones to find those that are stable, produce high yields of the bioproduct, and exhibit desired critical quality attributes (CQAs). While there are multiple CQAs that need to be monitored early in the development process, product yield, cell count and viability assessment remain the main attributes by which process conditions are optimized. Incorporating analytical techniques into…

Optimized Expression Systems for Increased Productivity in CHO DG44 Based Cell Line Development

by BPI Contributor

This webcast features: Dr. Rathangadhara Nammalwar, Team Lead, Cell Line Development for Protein-Based Therapeutics, Sartorius The Global Cell Line Development (CLD) services market is growing at an unprecedented pace. In 2020, the global revenues were about $700 million and are estimated to reach nearly $1.7 billion by 2028. Chinese hamster ovary (CHO) cells have been the most preferred host cell line for those CLD services, and they alone generated more than 50% of the global revenue in 2020. Key success…

Cell Media Analysis: A Critical Piece of the Bioprocessing Puzzle

by BPI Contributor

This webcast features: Graziella Piras, Bioprocess Segment Director, 908 Devices Cell culture medium remains a key component of traditional monoclonal antibody (mAb)-based biologics as well as newer modalities such as gene and cell therapies manufacturing. As such, cell culture media development and optimization continue to be an important focus for the biopharmaceutical industry. Increased analytical capabilities have provided new insights into the relationship between cell culture media, the cells they support, and ultimately the outcome of the final product. That greater insight offers more…

Scaling and Stirring: Success Factors in Scale Up with Single-Use Benchtop Bioreactors

by BPI Contributor

This webcast features: Cristina Bernal Martinez, Applications & Support Engineer, and Ann D’Ambruoso, Manager, Product Applications and Marketing, Getinge Single-use systems allow for a faster and easier workflow while simultaneously reducing the risk of errors and contamination in the development process. Nonetheless, fundamental bioreactor principles must be understood to correctly scale up in single-use bioreactors. Learn about the design factors in Applikon’s single-use bioreactors and review common scale-up strategies based on tip speed, power input, and kLa. Furthermore, shear stress…

TESSA Technology: A Plasmid-Free, Scalable System to Transform AAV Manufacture

by BPI Contributor

This webcast features: Dr. Weiheng Su, Principal Scientist, OXGENE Adenoassociated virus (AAV) is a popular choice of viral vector for new gene therapies, but manufacturing systems have not kept pace with biological advances, leaving these therapies costly, difficult to produce at scale, and subject to inherent batch-to-batch variability. In this webinar, Dr. Weiheng Su describes how rethinking AAV manufacture “from the ground up” allowed OXGENE to manipulate AAV’s natural relationship with adenovirus to address these challenges with their novel tetracycline-enabled…